We collect cookies to analyze our website traffic and performance; we never collect any personal data. Cookie Policy
Accept
NEW YORK DAWN™NEW YORK DAWN™NEW YORK DAWN™
Notification Show More
Font ResizerAa
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Reading: Elizabeth Holmes Points Fingers at Others and Says She Was a Believer
Share
Font ResizerAa
NEW YORK DAWN™NEW YORK DAWN™
Search
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Follow US
NEW YORK DAWN™ > Blog > Technology > Elizabeth Holmes Points Fingers at Others and Says She Was a Believer
Elizabeth Holmes Points Fingers at Others and Says She Was a Believer
Technology

Elizabeth Holmes Points Fingers at Others and Says She Was a Believer

Last updated: November 24, 2021 12:33 am
Editorial Board Published November 24, 2021
Share
SHARE
23theranos trial2 facebookJumbo

SAN JOSE, Calif. — Using charisma, poise and a smattering of scientific jargon, Elizabeth Holmes persuaded investors to give her nearly $1 billion to build Theranos, her blood testing start-up. That all came crashing down in 2018, after the company’s technology and business dealings were revealed to have major problems.

On Tuesday, Ms. Holmes used those same techniques to try to convince a jury that she was not guilty of fraud.

Taking the stand in her own defense for a third day, Ms. Holmes delivered her most substantial arguments to rebut the 11 counts of fraud that prosecutors have charged her with. She made eye contact with jurors and tilted her head to the side while making the case that she could not have intentionally deceived anyone about Theranos’s technology.

Ms. Holmes, 37, alternated between giving authoritative descriptions of Theranos’s scientific research and presenting herself as a naïve and ambitious founder who believed her company’s technology worked. She tried to reframe past incidents as misunderstandings about her intentions. She implied that her board of directors should have given her better counsel. She suggested that she had been too trusting of the doctors, scientists and engineers who worked at Theranos.

And she painted herself as an entrepreneur who cared deeply — maybe too much — about protecting her company’s brand and financial future, to the point that she made decisions that were later skewered by the prosecution as fraudulent.

The defense’s goal throughout the full day of testimony was to raise doubts in jurors’ minds about the prosecution’s case: that Ms. Holmes had deliberately claimed Theranos could revolutionize health care even though she knew the start-up’s technology was lacking. White-collar criminal cases are often highly technical and complicated and prosecutors face the burden of proving that the defendant intended to defraud.

“The whole ballgame comes down to knowledge and intent, and it’s the hardest thing for the prosecution to prove,” said Andrey Spektor, a lawyer at Bryan Cave Leighton Paisner and a former federal prosecutor in New York’s Eastern District.

The government’s best evidence about Ms. Holmes’s intent is circumstantial, coming from documents and the testimony of others, Mr. Spektor said. But Ms. Holmes could testify directly about what she knew and intended, he said.

The high-profile trial stands as a cautionary tale for Silicon Valley start-ups, which often embrace the same kind of hustle, ambition and change-the-world idealism that propelled Ms. Holmes to the top echelons of the industry. Despite the tech industry’s reliance on hype, few executives have been indicted on charges of lying to investors, making Theranos an outlier.

But as tech start-ups continue raising record-breaking sums of cash, some standard practices of governance and diligence have gone out the window, investors and entrepreneurs have said. If Ms. Holmes is convicted and sent to prison, the verdict could cast a pall over the good times, striking a new sense of caution among freewheeling founders.

On Tuesday, Ms. Holmes began a grueling day of testimony at 9 a.m. and stayed on the stand all day. She repeatedly hammered home a main theme of the defense: that she believed Theranos’s technology was working. Jurors were shown emails from various scientists and doctors who worked in the company’s lab describing successful studies, trials and other breakthroughs.

Channing Robertson, a Stanford University professor who joined Theranos’s board, told her that her ideas were “very promising,” Ms. Holmes testified. One email about Theranos’s tests to Ms. Holmes from Ian Gibbons, Theranos’s chief scientist, read: “Our immunoassays match the best that can be done in clinical labs.”

In a concession to one of the prosecution’s biggest pieces of evidence, Ms. Holmes admitted that she had personally added the logos of drug companies to Theranos’s validation reports without their permission. Those reports documented studies of Theranos’s blood tests done in partnership with pharmaceutical companies and had helped convince investors and partners that the start-up was the real deal.

Representatives from the drug makers Pfizer and Schering-Plough said earlier in the trial that their companies had not written or approved of the reports. But Ms. Holmes sent the reports with their logos to investors and partners as part of her pitch to get them to invest in and do business with Theranos.

Updated 

Nov. 23, 2021, 7:45 p.m. ET

Ms. Holmes said on Tuesday that she only added the logos to the reports to show that the work they described was done in partnership with the pharmaceutical companies. She said she didn’t intend to mislead investors.

“I’ve heard that testimony in this case and I wish I’d done it differently,” she said.

In response to testimony from lab workers who said they quit in frustration over Theranos’s shoddy science, Ms. Holmes said she never forced anyone to sign off on anything they didn’t agree with. She added that she would not have permitted Theranos to run any tests not approved of by the lab director, adding that she was not qualified to approve the tests herself.

She also brushed off one of the biggest claims by prosecutors: that Theranos was secretly doing most of its blood tests on commercially available machines from companies like Siemens, not its own. Theranos had promoted its small blood analyzers, known as Edisons and MiniLabs, as able to run hundreds of different tests on a drop of blood. But in reality, it could do only a dozen tests and had modified Siemens machines to run tests with smaller amounts of blood.

Ms. Holmes said she never told investors, partners, the public or her own board members that the company was doing most of its tests on Siemens devices because Theranos had made modifications to those machines. She said she worried Siemens or other competitors would copy those changes.

“This was an invention that we understood from our counsel we had to protect as a trade secret,” she said.

Ms. Holmes did not delve into her relationship with Ramesh Balwani, her boyfriend of more than a decade who was the chief operating officer of Theranos. The pair were indicted together but their cases were split last year. Mr. Balwani, who goes by “Sunny,” will be tried next year. Both have pleaded not guilty.

The pair kept their relationship a secret, but Ms. Holmes’s lawyers have said in filings that they expected her to tell jurors that Mr. Balwani, who is 18 years older than Ms. Holmes, emotionally and physically abused her during their relationship. They have also said they expect to call Mindy Mechanic, an expert witness focused on abusive relationships, to explain Ms. Holmes’s accusations.

Mr. Balwani’s role in the alleged fraud has been discussed nearly every day of the trial, but Ms. Holmes’s testimony only mentioned him when necessary, such as to describe an email thread used as evidence.

At the trial’s start, Judge Edward Davila of U.S. District Court for the Northern District of California, who is overseeing the case, instructed jurors not to speculate as to why Mr. Balwani was not present.

At the end of Tuesday’s proceedings, he warned jurors not to discuss the trial with family over the Thanksgiving weekend. “Do your best to pass the mashed potatoes and not engage in conversation with anyone,” he said.

Ms. Holmes’s testimony will resume next week.

Erin Woo contributed reporting.

You Might Also Like

The interoperability breakthrough: How MCP is changing into enterprise AI’s common language

SimilarWeb’s new AI utilization report reveals 5 stunning findings, together with explosive progress in coding instruments

Guardian brokers: New method may scale back AI hallucinations to under 1%

Shuhei Yoshida seems to be again on his lengthy profession at PlayStation whereas at Gamescom Latam 2025

Supercell’s Squad Busters transforms core gameplay with main replace

TAGGED:Computers and the InternetFrauds and SwindlingHolmes, Elizabeth (1984- )Medical DevicesStart-upsTests (Medical)The Washington MailTheranos Inc
Share This Article
Facebook Twitter Email Print

Follow US

Find US on Social Medias
FacebookLike
TwitterFollow
YoutubeSubscribe
TelegramFollow
Popular News
‘The Facemaker,’ a Grisly but Inspiring Story of Surgery During World War I
Art

‘The Facemaker,’ a Grisly but Inspiring Story of Surgery During World War I

Editorial Board June 8, 2022
The Way forward for Faucet-to-Earn Gaming: Overcoming Declining Consumer Retention
Cheese and laundry are the every day duties for Denis Leary military comedy ‘Going Dutch’
Pentagon Faults Review of Deadly Airstrike but Finds No Wrongdoing
From Burnout to Stability: 6 Self-Care Habits That’ll Change Your Life in 2025

You Might Also Like

Sakana introduces new AI structure, ‘Continuous Thought Machines’ to make fashions motive with much less steering — like human brains
Technology

Sakana introduces new AI structure, ‘Continuous Thought Machines’ to make fashions motive with much less steering — like human brains

May 13, 2025
Sakana introduces new AI structure, ‘Continuous Thought Machines’ to make fashions motive with much less steering — like human brains
Technology

OpenAI simply mounted ChatGPT’s most annoying enterprise downside: meet the PDF export that modifications all the things

May 12, 2025
New totally open supply imaginative and prescient encoder OpenVision arrives to enhance on OpenAI’s Clip, Google’s SigLIP
Technology

New totally open supply imaginative and prescient encoder OpenVision arrives to enhance on OpenAI’s Clip, Google’s SigLIP

May 12, 2025
Glass Imaging raises M to make use of AI to enhance digital picture high quality
Technology

Glass Imaging raises $20M to make use of AI to enhance digital picture high quality

May 12, 2025

Categories

  • Health
  • Sports
  • Politics
  • Entertainment
  • Technology
  • World
  • Art

About US

New York Dawn is a proud and integral publication of the Enspirers News Group, embodying the values of journalistic integrity and excellence.
Company
  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • Accessibility Statement
Contact Us
  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability
Term of Use
  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices
© 2024 New York Dawn. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?